SCHEMBL1799401

SCHEMBL1799401

O=C(COCC(=O)Nc1ccc(-c2ccccc2)cc1C(=O)O)Nc1ccc(-c2ccccc2)cc1C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.64
KDM4E B2RXH2 2/20 0.57
POLB P06746 2/20 0.57
ALDH1A1 P00352 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SERPINE1 P05121 5/20 0.51
HCAR2 Q8TDS4 5/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ACLY P53396 1/20 0.49
DHFR P00374 1/20 0.49
HNF4A P41235 1/20 0.49
MCL1 Q07820 1/20 0.49
ACMSD Q8TDX5 1/20 0.49
CASP3 P42574 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
G6PD P11413 1/20 0.47
IGF2BP2 Q9Y6M1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1800597 0.92 PTPN1 (0.56) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL1800870 0.89 SERPINE1 (0.53) PTPN1KDM4EPOLBALDH1A1SERPINE1
SCHEMBL1800596 0.87 ALDH1A1 (0.54) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL418006 0.85 SERPINE1 (0.65) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL1799563 0.84 KDM4E (0.52) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL22650196 0.84 PTPN1 (0.66) PTPN1KDM4EALDH1A1SERPINE1HCAR2
SCHEMBL1798766 0.83 HCAR2 (0.47) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL1797284 0.82 CDC7 (0.48) PTPN1KDM4EPOLBALDH1A1SERPINE1
SCHEMBL1797277 0.82 AAK1 (0.46) PTPN1KDM4EPOLBALDH1A1HSD17B10
SCHEMBL1016816 0.81 RXFP1 (0.46) PTPN1KDM4EPOLBALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US claimed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US claimed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 PTPN1 853/4885KDM4E 4309/4885POLB 2674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.